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###### Key messages

Relapse following treatment of severe acute malnutrition (SAM) is poorly defined and scarcely measured across programs and research.Reported relapse ranges from 0% to 37% of children following SAM treatment, with the highest proportions occurring within 6 months post‐discharge. The data across studies are largely not comparable due to different treatment protocols, various follow‐up periods, and inconsistent reporting of relapse as a point prevalence (not cumulative), cumulative prevalence, and incidence rate.Lower anthropometric measurements on admission to and discharge from SAM treatment are consistent risk factors for relapse. Illness is frequently observed at the time of relapse.A standardized definition of relapse and a maximum acceptable relapse rate are needed.

1. INTRODUCTION {#mcn12702-sec-0003}
===============

Around 17 million children worldwide suffer from severe acute malnutrition (SAM), defined as having a weight‐for‐height *z*‐score (WHZ) less than −3 *SD* or a mid‐upper arm circumference (MUAC) less than 115 mm (United Nations Children\'s Fund, World Health Organization, & World Bank Group, [2017](#mcn12702-bib-0033){ref-type="ref"}). Estimates reveal that worldwide numbers of children who suffer from acute malnutrition have decreased very little (only 11% over the past 20 years), particularly when compared with progress made in reducing other malnutrition indicators, such as stunting (Annan, Webb, & Brown, [2014](#mcn12702-bib-0003){ref-type="ref"}). The immediate consequences of SAM are life threatening, as a child with SAM is approximately nine times more likely to die than a non‐malnourished child (Black et al., [2008](#mcn12702-bib-0013){ref-type="ref"}).

Although most of the research conducted around SAM addresses the causes, short‐term consequences, and treatment methods for achieving immediate recovery, little is known about the overall health and nutrition of children following discharge. A small body of evidence is emerging from the few studies that followed children after treatment for SAM, demonstrating poor post‐discharge outcomes after initial recovery including mortality, morbidity, and functional implications (Bahwere, Mtimuni, Sadler, Banda, & Collins, [2012](#mcn12702-bib-0007){ref-type="ref"}; Lelijveld et al., [2016](#mcn12702-bib-0023){ref-type="ref"}). One of the most immediate outcomes that needs to be understood and addressed is relapse to SAM. To find appropriate, scalable solutions that can tackle relapse, there is need to identify the overall burden of relapse in different contexts as well as better understand potential risk factors and consequences associated with relapse. Although standard community‐based management of acute malnutrition (CMAM) programme report forms based on the Sphere Minimum Standard guidelines do include space to record relapse up to 2 months post‐discharge, without standardized guidance on how to capture relapse accurately or an evidence‐base to prove the importance of allocating resources to do so, it is infrequently reported.

In this study, we aimed to systematically review current literature and conduct secondary data analyses on a dataset from Malawi to better understand relapse rates in children following recovery from SAM treatment.

2. METHODS {#mcn12702-sec-0004}
==========

2.1. Search strategy {#mcn12702-sec-0005}
--------------------

This literature review focused on retrieving and analysing peer reviewed publications as well as other programme reports, evaluations, and grey literature. This was conducted through three main search components. The first consisted of reviewing two previously conducted literature reviews (Akparibo, Lee, & Booth, [2017](#mcn12702-bib-0001){ref-type="ref"}; Bahwere, [2016](#mcn12702-bib-0006){ref-type="ref"}) to include only articles reporting relapse within 18 months of discharge from SAM treatment. The second search component of this review included a computerized search of PubMed and Google Scholar between January 1, 2015, and October 15, 2017, designed to update the previous reviews. The following search terms were used: "protein energy malnutrition" (Mesh), "severe acute malnutrition" (Mesh), "acute malnutrition," "malnourish\*," "undernourish\*," "severe wasting," "severely wasted," "severely undernourished," "severe undernutrition," "child\*," "infant\*," "preschool\*," "toddler\*," "relapse," "readmission," "after recovery," "after discharge," "after cured," "post‐discharge," "post‐SAM," or "long term." Reference lists of articles were also screened for further relevant publications. To identify ongoing research and other relevant grey literature, the websites of NGOs, donors, and knowledge‐sharing platforms such as the Emergency Nutrition Network were searched. Co‐authors of this paper inquired to their respective networks of researchers in order to identify further unpublished reports or ongoing studies, as well as any relevant datasets for secondary data analysis. All searches were limited to studies published in English, Spanish, or French.

2.2. Study selection {#mcn12702-sec-0006}
--------------------

Relevant articles were obtained and included in this review if they met inclusion and exclusion criteria based on three main items---population, intervention, and outcome. This review included studies if they involved children under the age of 5 years old who received treatment for SAM. Only studies that used definitions of SAM by anthropometric measurements based upon the National Center for Health Statistics child growth references, World Health Organization (WHO) child growth standards, and/or MUAC were included.

The included literature consisted of interventions specifically designed to treat children with SAM, namely, inpatient care using therapeutic milks and outpatient care using ready‐to‐use therapeutic foods. There were no parameters around location or whether the context was considered a humanitarian emergency or development setting. The main outcome of interest in this review was relapse to SAM following the treatment of SAM. The concept of relapse is not well defined in the literature; the distinction between "relapse" and a new episode of SAM is especially difficult to differentiate. We therefore set a generous time limit of 18 months post‐discharge as possible relapse for the purposes of the search.

2.3. Screening process and data extraction {#mcn12702-sec-0007}
------------------------------------------

We screened all publications identified in the two previous literature reviews and updated electronic searches by reading the titles and abstracts to determine initial relevance. After removing duplications, a second screening process consisted of reading full texts of the remaining articles and those that met the inclusion/exclusion criteria were retained. Data were extracted into an excel file that included information on authors, date of publication, county, title, type of paper, study design, type of intervention or programme to treat SAM, admission and discharge criteria for the treatment of SAM, follow‐up length and schedule, relapse rates, and other findings and comments.

We felt that applying a systematic quality assurance checklist would be too limiting given such few studies regarding post‐SAM relapse exist. Therefore, we aimed to include all literature that may provide relevant information on the topic. We evaluated the strengths and weaknesses of each research article and programme report independently to ensure that quality of study design was considered when interpreting results.

2.4. Secondary data analysis {#mcn12702-sec-0008}
----------------------------

For the secondary data analysis, one dataset was made available: a retrospective follow‐up of children treated in a CMAM programme in Dowa, Malawi, between 2002 and 2005, with follow‐up periods ranging from 1 to 32 months post‐discharge (Bahwere et al., [2012](#mcn12702-bib-0007){ref-type="ref"}). We assessed the association of child and household characteristics with odds of relapse to SAM up to 6 and 12 months post‐discharge from treatment, using logistic regression and STATA 14 software. A long list of potential exposure variables was created prior to sourcing secondary data, including child anthropometry during treatment, child health history, family characteristics, and household characteristics. All available variables from this list of potential exposures were included in analysis.

3. RESULTS {#mcn12702-sec-0009}
==========

3.1. Search results {#mcn12702-sec-0010}
-------------------

A flowchart detailing the process of study selection is shown in Figure [S1](#mcn12702-supitem-0002){ref-type="supplementary-material"} **.** Ultimately, 26 articles and reports were included in the final qualitative synthesis, including 21 original research studies, four programme evaluation reports, and one coverage survey (Table [1](#mcn12702-tbl-0001){ref-type="table"}). Of the published studies, 13 were prospective longitudinal cohorts; three were cross‐sectional studies; three retrospective cohorts; and two were secondary data analysis.

###### 

Characteristics of articles and reports identified in the review as specifically addressing relapse following severe acute malnutrition treatment

<table><thead><tr class="header"><th style="text-align: left;">First author/date/country</th><th style="text-align: left;">Type of paper/study design</th><th style="text-align: left;">Type of programme</th><th style="text-align: left;">Admission criteria (SAM definition)</th><th style="text-align: left;">Discharge criteria</th><th style="text-align: left;">Follow‐up length</th><th style="text-align: left;">Follow‐up schedule</th><th style="text-align: left;">Indicator reported</th><th style="text-align: left;">Relapse rate</th><th style="text-align: left;">Findings, comments, and limitations</th></tr></thead><tbody><tr class="odd"><td style="text-align: left;">Ashraf/2012/Bangladesh</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">Day care</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>WAZ &lt; −3</p><p>oedema</p></td><td style="text-align: left;">WHM ≥ 80%</td><td style="text-align: left;">6 months</td><td style="text-align: left;">Weekly (2 visits), fortnightly (5 visits), quarterly (3 visits)</td><td style="text-align: left;">Incidence</td><td style="text-align: left;">17.8%</td><td style="text-align: left;">Observed persistent stunting, high prevalence of illness in first 3 months, study experienced high drop‐out rate</td></tr><tr class="even"><td style="text-align: left;">Bahwere/2008/Malawi</td><td style="text-align: left;">Original research/cross‐sectional</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>WHM &lt; 70%</p><p>MUAC &lt; 110 mm</p><p>oedema</p></td><td style="text-align: left;">WHM ≥ 80%</td><td style="text-align: left;">15.6 months (median length)</td><td style="text-align: left;">3, 12 months</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">3% (35.7% for HIV+ and 2% for HIV−)</td><td style="text-align: left;">Recommend more RUTF for HIV+ children, continued feeding for HIV+ children, and link CMAM model with HIV treatment</td></tr><tr class="odd"><td style="text-align: left;">Beau/1993/Senegal</td><td style="text-align: left;">Original research/cross‐sectional</td><td style="text-align: left;">Facility‐based</td><td style="text-align: left;"><p>WHZ &lt; −2</p><p>oedema</p></td><td style="text-align: left;">WHM ≥ 80%</td><td style="text-align: left;">12 months</td><td style="text-align: left;">Once at endpoint</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">10.1%</td><td style="text-align: left;">Suggests return to an unfavourable environment and poor adoption of nutrition counselling messages explain high relapse rates</td></tr><tr class="even"><td style="text-align: left;">Begashaw/2013/Nigeria</td><td style="text-align: left;">Coverage survey</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>MUAC &lt; 115 mm</p><p>oedema</p></td><td style="text-align: left;">MUAC ≥ 125 mm</td><td style="text-align: left;">Unclear; mothers were asked if child had previously been admitted and discharged</td><td style="text-align: left;">N/A (readmissions)</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">25%</td><td style="text-align: left;">Observed high prevalence of illness at time of relapse; rates rely of caregivers' report of prior treatment</td></tr><tr class="odd"><td style="text-align: left;">Bhandai/2017/India</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>oedema</p></td><td style="text-align: left;">WHZ ≥ −2</td><td style="text-align: left;">16 weeks</td><td style="text-align: left;">Once at endpoint</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">37.4% to SAM, 48% to MAM (42.4% local diet, 40.7% conventional RUTF, 29.2% local RUTF)</td><td style="text-align: left;">RUTF resulted in lower relapse rates than fortified home‐based diet</td></tr><tr class="even"><td style="text-align: left;">Binns/2016/Malawi</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>MUAC &lt; 115 mm</p><p>oedema</p></td><td style="text-align: left;">MUAC ≥ 125 mm for 2 consecutive weeks</td><td style="text-align: left;">3 months</td><td style="text-align: left;">Fortnightly</td><td style="text-align: left;">Incidence</td><td style="text-align: left;">1.9%</td><td style="text-align: left;">MUAC deemed an appropriate discharge criterion; early detection of SAM may reduce relapse. Cure rate for initial treatment programme was low (63%) due to early discharge. Children in SFP during follow‐up period</td></tr><tr class="odd"><td style="text-align: left;">Burrell/2017/Gambia</td><td style="text-align: left;">Original research/retrospective secondary data analysis</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>MUAC &lt; 115 mm</p></td><td style="text-align: left;"><p>MUAC ≥ 125 mm</p><p>WHZ ≥ −2</p></td><td style="text-align: left;">1–4 weeks</td><td style="text-align: left;">N/A (readmissions)</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">6% (7.1% and 3.8% for MUAC and WHZ discharge)</td><td style="text-align: left;">No statistical difference in relapse rates between discharge criteria using MUAC versus WHZ; no established follow‐up procedure; all relapses were defined as self‐referring readmissions. Likely an underestimation of true relapse</td></tr><tr class="even"><td style="text-align: left;">Burza/2016/India</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>MUAC &lt; 115 mm</p><p>oedema</p></td><td style="text-align: left;">MUAC ≥ 120 mm for 2 consecutive weeks</td><td style="text-align: left;">18 months</td><td style="text-align: left;">Quarterly</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">9.1%, 2.9%, 2.1%, 2.8%, and 0% at 3, 6, 9, 12, and 18 months, respectively</td><td style="text-align: left;">Associations with relapse include: seasonality, use of health services, lower standard of living, less time outside the programme, low HAZ at time of discharge</td></tr><tr class="odd"><td style="text-align: left;">Ciliberto/2005/Malawi</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">CMAM versus facility‐based</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>oedema</p></td><td style="text-align: left;">WHZ &gt; −2</td><td style="text-align: left;">6 months</td><td style="text-align: left;">Once at endpoint</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">6.9% (6.2% and 10.6% for home‐RUTF and inpatient)</td><td style="text-align: left;">Receiving home‐based RUTF is associated with lower risk of relapse</td></tr><tr class="even"><td style="text-align: left;">Cuneo/2017/Haiti</td><td style="text-align: left;">Original research/retrospective analysis</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>MUAC &lt; 115 mm</p></td><td style="text-align: left;">Operationally: WHZ &gt; −1 for 2 consecutive weeks; data analysis of “cured”: 15% weight gain</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">N/A (readmissions)</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">6% over the total 5 years (5%, 3%, 0%, 8%, 4%, 20% for each year of 2009–2013, respectively); only 56% cured at discharge</td><td style="text-align: left;">Low cure rate at discharge reflects programme quality, which likely impacts relapse rates</td></tr><tr class="odd"><td style="text-align: left;">Dani/2016/India</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">CMAM‐providing locally made therapeutic food for 90 days</td><td style="text-align: left;"><p>WHZ ≤ −3</p><p>WAZ ≤ −3</p></td><td style="text-align: left;">Unclear</td><td style="text-align: left;">6 months</td><td style="text-align: left;">Once at endpoint</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">3% SAM and 11% severely underweight</td><td style="text-align: left;">Higher relapse rates to underweight may be due to stunting following SAM</td></tr><tr class="even"><td style="text-align: left;">Grellety/2017/DRC</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">CMAM + cash transfer program</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>MUAC &lt; 115 mm</p><p>oedema</p></td><td style="text-align: left;">MUAC ≥ 125 mm or WHZ ≥ −1.5 for 2 consecutive weeks</td><td style="text-align: left;">3–5 months (6 months after admission)</td><td style="text-align: left;">Monthly</td><td style="text-align: left;">Incidence</td><td style="text-align: left;">12.6% SAM, 28% MAM, (CMAM + CTP: 3% SAM and 13% MAM; CMAM only: 11% SAM and 44% MAM)</td><td style="text-align: left;">An unconditional cash transfer in combination with CMAM led to significantly lower relapse, time of follow‐up after discharge varied between participants</td></tr><tr class="odd"><td style="text-align: left;">Khanum/1998/Bangladesh</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">Facility based, day‐care, domiciliary</td><td style="text-align: left;"><p>WHM &lt; 60%</p><p>oedema</p></td><td style="text-align: left;">WHM ≥ 80%</td><td style="text-align: left;">12 months</td><td style="text-align: left;">Fortnightly</td><td style="text-align: left;">Incidence</td><td style="text-align: left;">1%</td><td style="text-align: left;">All study participants lived &lt;10 km of the health facility; access to healthcare services may explain low relapse rates</td></tr><tr class="even"><td style="text-align: left;">Magnin/2017/Madagascar</td><td style="text-align: left;">Original research/retrospective analysis</td><td style="text-align: left;">CMAM</td><td style="text-align: left;">WHZ &lt; −3</td><td style="text-align: left;">WHZ &gt; −1</td><td style="text-align: left;">1 year</td><td style="text-align: left;">Once at endpoint</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">1%</td><td style="text-align: left;">Being younger, higher admission WHZ, and use of chlorine water treatment increased likelihood of maintaining recovery; when children were lost to follow‐up, data on other children who had participated in the programme were used</td></tr><tr class="odd"><td style="text-align: left;">Mengesha/2016/Ethiopia</td><td style="text-align: left;">Original research/retrospective analysis</td><td style="text-align: left;">CMAM</td><td style="text-align: left;">MUAC &lt; 110 mm</td><td style="text-align: left;">MUAC ≥ 110 and 15% weight gain</td><td style="text-align: left;">2 months</td><td style="text-align: left;">N/A (readmissions)</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">22%</td><td style="text-align: left;">Low admission MUAC criteria and % weight gain as discharge criteria may explain higher relapse rates</td></tr><tr class="even"><td style="text-align: left;">Nyirenda/2010/Ethiopia</td><td style="text-align: left;">Programme evaluation</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>WHM &lt; 70%</p><p>MUAC &lt; 110 mm</p><p>oedema</p></td><td style="text-align: left;">WHM ≥ 85% or 15% weight gain for 2 consecutive weeks</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">N/A (readmissions)</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">1%, 1.3%, 1.8% in 2007, 2008, 2009, respectively</td><td style="text-align: left;">No established follow‐up procedure; all relapses were defined as self‐referring readmissions. Likely an underestimation of true relapse.</td></tr><tr class="odd"><td style="text-align: left;">Pecoul/1992/Niger</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">Facility based</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>oedema</p></td><td style="text-align: left;">WHZ ≥ −3</td><td style="text-align: left;">3–18 months</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">0%</td><td style="text-align: left;">Small sample size, outdated treatment protocol, high mortality and default rate during treatment, no follow‐up occurred between discharge and 3 months</td></tr><tr class="even"><td style="text-align: left;">Perra/1995/Guinea Bissau</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">Facility‐based</td><td style="text-align: left;">WAM &lt; 60%</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">18 months</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">Incidence</td><td style="text-align: left;">1%</td><td style="text-align: left;">Children treated for SAM had better outcomes than those who had not been treated; response to prior study saying treatment was a waste. One cross‐sectional survey at 18 months follow‐up is likely to miss relapses that take place closer to the time of discharge.</td></tr><tr class="odd"><td style="text-align: left;">Querubin/2006/Sudan</td><td style="text-align: left;">Programme evaluation</td><td style="text-align: left;">Facility based and CMAM</td><td style="text-align: left;"><p>WHM &lt; 70%</p><p>MUAC &lt; 110 mm</p></td><td style="text-align: left;">WHM ≥ 80% or MUAC ≥ 120 for 2 consecutive weeks</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">Unclear, readmission?</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">0%</td><td style="text-align: left;">Report was written using programme monitoring data and does not include much detail regarding follow‐up procedures or duration</td></tr><tr class="even"><td style="text-align: left;">van Roosmalen‐Weibenga/1987/Tanzania</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">Facility‐based</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">12 months</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">13%</td><td style="text-align: left;">Difficult to compare results as treatment protocols are outdated</td></tr><tr class="odd"><td style="text-align: left;">Singth/2016/India</td><td style="text-align: left;">Original research/prospective longitudinal cohort</td><td style="text-align: left;">Facility based</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>MUAC &lt; 115 mm</p><p>oedema</p></td><td style="text-align: left;">15% weight gain</td><td style="text-align: left;">Approximately 1.5 months</td><td style="text-align: left;">1 week, then every 15 days</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">4.9% total (8%, 3%, 5% for 0–6, 7–24, 25–59 months, respectively)</td><td style="text-align: left;">Suggested better integration between facility‐based and community‐based treatment to reduce relapse</td></tr><tr class="even"><td style="text-align: left;">Somasse/2015/Burkina Faso</td><td style="text-align: left;">Original research/prospective longitudinal cohort</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>MUAC &lt; 110 mm</p><p>oedema</p></td><td style="text-align: left;">WHZ &gt; −2</td><td style="text-align: left;">12 months</td><td style="text-align: left;">Quarterly</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">11% SAM; 16% AM</td><td style="text-align: left;">High lost to follow‐up (34%), which may lead to underestimation of relapse; MUAC upon discharge below 125 mm, no oil/fat consumption, and incomplete vaccination were all associated with relapse</td></tr><tr class="odd"><td style="text-align: left;">Tadese/2017/Ethiopia</td><td style="text-align: left;">Original research/prospective longitudinal cohort</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>MUAC &lt; 110 mm</p><p>oedema</p></td><td style="text-align: left;">15% weight gain</td><td style="text-align: left;">14 weeks after admission</td><td style="text-align: left;">4, 8, and 14 weeks after admission (about 2–6 weeks after discharge)</td><td style="text-align: left;">Point prevalence</td><td style="text-align: left;">Recovered: 30% to SAM and 50% to MAMtotal: 35% to SAM and 38% to MAM</td><td style="text-align: left;">Many children discharged prior to anthropometric recovery; proportion of children readmitted was significantly higher among children with most severe degree of wasting on admission</td></tr><tr class="even"><td style="text-align: left;">Taylor/2002/Sudan</td><td style="text-align: left;">Programme evaluation/programme M&amp;E</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>oedema</p></td><td style="text-align: left;">WHM &gt; 75% for 4 consecutive weeks</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">Unclear, readmission?</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">1%</td><td style="text-align: left;">Report was written using programme monitoring data and does not include much detail regarding follow‐up procedures or duration</td></tr><tr class="odd"><td style="text-align: left;">Tsinuel/2015/Ethiopia</td><td style="text-align: left;">Original research/prospective cohort</td><td style="text-align: left;">CMAM</td><td style="text-align: left;"><p>MUAC &lt; 110 mm</p><p>oedema</p></td><td style="text-align: left;">MUAC &gt; 110 mm and 20% weight gain for 2 consecutive weeks</td><td style="text-align: left;">12 months</td><td style="text-align: left;">Monthly</td><td style="text-align: left;">Incidence</td><td style="text-align: left;">By then end, 15% to SAM in post‐SAM, 1% in healthy controls</td><td style="text-align: left;">Post‐SAM children had higher risk for AM than controls; MUAC, HAZ, food security, and IYCF were associated with relapse; discharge using % weight gain may increase relapse rates</td></tr><tr class="even"><td style="text-align: left;">UNICEF/2012/Kenya</td><td style="text-align: left;">Programme evaluation/programme M&amp;E</td><td style="text-align: left;">Facility‐based and CMAM</td><td style="text-align: left;"><p>WHZ &lt; −3</p><p>MUAC &lt;115 mm</p></td><td style="text-align: left;">Unclear</td><td style="text-align: left;">12 months?</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">Unclear</td><td style="text-align: left;">6.1% inpatient, 3.2% outpatient</td><td style="text-align: left;">Health workers stated that sharing RUTF negatively affects relapse.</td></tr></tbody></table>

*Note*. AM: acute malnutrition; CMAM: community‐based management of acute malnutrition; CTP: cash transfer programme; HIV: human immunodeficiency virus; MAM: moderate acute malnutrition; M&E: monitoring and evaluation; MUAC: mid‐upper arm circumference; RUTF: ready‐to‐use therapeutic food; SAM: severe acute malnutrition; SFP: supplementary feeding programme; WAZ: weight‐for‐age *z*‐score; WHM: weight‐for‐height percent of median; WHZ: weight‐for‐height *z*‐score.

3.2. Definition of relapse and relapse rates {#mcn12702-sec-0011}
--------------------------------------------

The definition of relapse varied across studies and programme reports. There was also differing anthropometric admission and discharge criteria, duration of follow‐up, frequency of data collection points, and data collection methods (i.e., active follow‐up visits vs. readmission based on passive, self‐referrals; Table [1](#mcn12702-tbl-0001){ref-type="table"}). Generally, relapse was defined as a child presenting at least once with SAM within a specified time period following discharge (or default) from SAM treatment. Anthropometric criteria for relapse typically coincided with the anthropometric admission criteria for initial SAM treatment but sometimes also included the development of moderate acute malnutrition (MAM). No standard length of time was used, ranging from 1 week to 18 months after discharge across the studies. Most of the original research studies conducted active follow‐up visits, whereas evaluations and programme reports tended to report relapse based on readmission.

The proportion of children who relapsed following treatment for SAM spanned from 0% to 37% at various points following discharge (Figure [1](#mcn12702-fig-0001){ref-type="fig"}). (The denominators to these proportions varied, including children discharged and/or defaulted from SAM treatment programs.) Relapse tended to occur more frequently during the first 6 months following discharge. For example, a 2016 study in India that followed children on a quarterly basis for 18 months after discharge found that children were more likely to relapse in the first 3 months (9.1%) versus 6 months (2.9%), 9 months (2.1%), 12 months (2.8%), and 18 months (0%; Burza et al., [2016](#mcn12702-bib-0015){ref-type="ref"}). A 2015 longitudinal study in Ethiopia demonstrated the probability of experiencing a new episode of acute malnutrition (AM) was 26% and 7.5% for 6 and 12 months, respectively (Tsinuel, Alemseged, Philips, Paluku, & team, [2015](#mcn12702-bib-0032){ref-type="ref"}). When including both MAM and SAM in the definition of relapse, the proportion of relapse increases dramatically, from 38% to 86% at 3 months in India (Bhandari et al., [2016](#mcn12702-bib-0011){ref-type="ref"}), 30% to 80% over 3.5 months in Ethiopia (Tadesse, Worku, Berhane, & Ekstrom, [2017](#mcn12702-bib-0030){ref-type="ref"}), 13% to 41% over 6 months in the Democratic Republic of Congo (Grellety et al., [2017](#mcn12702-bib-0020){ref-type="ref"}), and 15% to 44% over 12 months in Ethiopia (Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}) for relapse to SAM and AM, respectively.

![Relapse rates presented in literature according to the duration of follow‐up after discharge from treatment of SAM. AM: acute malnutrition; SAM: severe acute malnutrition. When relapse rates were disaggregated between those who met discharge criteria and those who did not, rates of those who met discharge criteria were included. However, it was not always clear if all children included in the relapse rates were discharged as recovered. Also, some studies included relapse to AM where others included only relapse to SAM. Lastly, rates also vary between those that are point prevalence or cumulative; thus, relapse rates in Figure [1](#mcn12702-fig-0001){ref-type="fig"} are not fully comparable. Data measured: † fortnightly, ‡ monthly, § quarterly, ‖ varied, ¶ readmission/unclear, and †† once at endpoint. \* Studies with relapse defined as relapse to AM (including MAM or SAM). Such studies that report relapse back to MAM or SAM are those where children are discharged at a point in which they are deemed "not malnourished" and therefore a "relapse" to MAM is indeed a true regression in nutritional status](MCN-15-e12702-g001){#mcn12702-fig-0001}

In this review, only one study included a true control group of non‐malnourished counterparts for which to compare excess relapse (Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}). This 2015 longitudinal study in Ethiopia followed children after SAM treatment as well as matched nonwasted community controls for 1 year and found 15% relapse in post‐SAM group yet 1.2% of the control children became severely malnourished in the same time period. The incidence rate was 1.27 and 0.09 per 100 person‐months for post‐SAM and controls, respectively (Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}).

Indicators of relapse were reported as a mixture of point prevalence (i.e., how many children were in a state of relapse at one specific point in time) and a cumulative proportion or incidence rate (i.e., how many children relapsed or how many relapses occurred throughout a certain period of time). Those who reported relapse as a cumulative proportion or incidence rate tended to be higher than point prevalence, as they likely captured more relapse simply by the nature of more frequent data collection points. For example, when post‐discharge children are only measured at one point in time, such as at 12 months after discharge, it is likely that many children relapsed and recovered prior to that 12‐month follow‐up time that are not accounted for in this statistic. Also, point prevalence does not account for multiple episodes of relapse that occur per child prior to that point in time. The difference between reporting relapse as point prevalence and cumulative incidence is seen in the 2015 Ethiopian study where both indicators were calculated. In this study, reported relapse is 1% as a point prevalence at 12 months post‐discharge (meaning only 1% of children was in a state of relapse at the time of 12 months post‐discharge) and yet relapse is 15% cumulative incidence over the course of the entire 12 months (Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}).

Consistently, studies and programme evaluations reported that children who defaulted or were discharged prior to reaching recommended anthropometric discharge criteria had higher risk for relapse (Akparibo et al., [2017](#mcn12702-bib-0001){ref-type="ref"}; Ashworth, [2001](#mcn12702-bib-0005){ref-type="ref"}; Binns et al., [2016](#mcn12702-bib-0012){ref-type="ref"}; Burza et al., [2016](#mcn12702-bib-0015){ref-type="ref"}; Pecoul, Soutif, Hounkpevi, & Ducos, [1992](#mcn12702-bib-0027){ref-type="ref"}; Tadesse et al., [2017](#mcn12702-bib-0030){ref-type="ref"}). In Niger, those who defaulted during treatment had 7.1 times higher risk of death and were more likely to relapse at 3 months than those who were discharged as recovered (Pecoul et al., [1992](#mcn12702-bib-0027){ref-type="ref"}). A 2016 study in India observed relapse as high as 52% of children who defaulted from SAM treatment (Burza et al., [2016](#mcn12702-bib-0015){ref-type="ref"}). Including defaulters in the definition of relapse likely inflates the proportion of relapse due to the inability to determine whether those defaulters ever reached a state of recovery (and thus truly "relapsed" back to being malnourished again) or remained malnourished throughout the time after leaving the treatment programme to the follow‐up point. The latter case is not a true relapse, rather a prolonged case of unresolved acute malnutrition.

The strongest, most consistent risk factor associated with relapse was having lower anthropometric measurements upon admission to and discharge from treatment of SAM (Ashraf et al., [2012](#mcn12702-bib-0004){ref-type="ref"}; Bahwere et al., [2008](#mcn12702-bib-0008){ref-type="ref"}; Beau, [1993](#mcn12702-bib-0009){ref-type="ref"}; Begashaw, [2013](#mcn12702-bib-0010){ref-type="ref"}; Binns et al., [2016](#mcn12702-bib-0012){ref-type="ref"}; Khanum, Ashworth, & Huttly, [1998](#mcn12702-bib-0022){ref-type="ref"}; Somasse, Dramaix, Bahwere, & Donnen, [2015](#mcn12702-bib-0028){ref-type="ref"}; Tadesse et al., [2017](#mcn12702-bib-0030){ref-type="ref"}; Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}). Illness was observed at the time of relapse in eight studies (Ashraf et al., [2012](#mcn12702-bib-0004){ref-type="ref"}; P. Bahwere et al., [2008](#mcn12702-bib-0008){ref-type="ref"}; Begashaw, [2013](#mcn12702-bib-0010){ref-type="ref"}; Binns et al., [2016](#mcn12702-bib-0012){ref-type="ref"}; Khanum et al., [1998](#mcn12702-bib-0022){ref-type="ref"}; Somasse et al., [2015](#mcn12702-bib-0028){ref-type="ref"}; Tadesse et al., [2017](#mcn12702-bib-0030){ref-type="ref"}; Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}). Several authors suggested that children who are discharged as recovered from SAM treatment based on anthropometrics alone may not have experienced full immunologic recovery, leaving them susceptible to infection and subsequent relapse. Although rarely measured, micronutrient deficiencies were not associated with relapse (Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}). Poor linear growth and stunting were also consistently observed post‐discharge (Paluku Bahwere, [2016](#mcn12702-bib-0006){ref-type="ref"}; Lelijveld et al., [2016](#mcn12702-bib-0023){ref-type="ref"}; Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}). Data are mixed regarding significant associations between relapse and household‐level factors, such as socio‐economic status, feeding practices, and sanitary living conditions (Burza et al., [2016](#mcn12702-bib-0015){ref-type="ref"}; Kerac et al., [2014](#mcn12702-bib-0021){ref-type="ref"}; Magnin, Stoll, Voahangy, & Jeannot, [2017](#mcn12702-bib-0024){ref-type="ref"}; Somasse et al., [2015](#mcn12702-bib-0028){ref-type="ref"}; Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}). Results are inconclusive regarding the effect of seasonality and food security on relapse (Burza et al., [2016](#mcn12702-bib-0015){ref-type="ref"}; Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}). Unconditional cash transfers during and following the treatment of SAM led to a decrease in relapse rates (Grellety et al., [2017](#mcn12702-bib-0020){ref-type="ref"}).

3.3. Secondary data analyses {#mcn12702-sec-0012}
----------------------------

The database of children from a CMAM programme in Dowa, Malawi contained 1,361 records with a mean follow‐up period of 15 months (range 1--32 months). Stratifying the data by length of follow‐up found that 14% (16/118) and 12% (33/269) of children relapsed by 6 and 12 months post‐discharge, respectively. Proportion of relapse is similar when presenting only those discharged as recovered: 12% (14/113) and 13% (29/225), respectively. Loss to follow‐up and/or survivor bias, may be underestimating the relapse rate, especially among those who defaulted from treatment. There was no significant difference in odds ratio of relapse at 6 nor 12 months when regressed against age at admission, sex, oedema at admission, diarrhoea at admission, fever at admission, cough at admission, MUAC at admission, mother not alive, father not alive, attendance to supplementary feeding program, or MUAC at discharge, respectively. Being an orphan was associated with five times greater odds of relapse at 12 months\' post‐discharge (95% CI \[1.7, 12.4\], *P* = 0.003; Table [S1](#mcn12702-supitem-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#mcn12702-sec-0013}
=============

Results of this review have highlighted that relapse is poorly defined and scarcely measured across programs and research alike. The lack of a standard definition of relapse following the treatment of SAM has led to relapse rates that are largely not comparable, with varying follow‐up time periods and inconsistent reporting between point prevalence, cumulative prevalence, and incidence indicators.

Different treatment protocols, such as varying admission and discharge criteria, likely add to the wide range of relapse rates. For example, discharge based on percent weight gain has been shown to be less effective than MUAC or WHZ cut‐offs in reaching a true recovery (Dale, Myatt, Prudhon, & Briend, [2013](#mcn12702-bib-0018){ref-type="ref"}), and using a lower MUAC cut‐off for admission criteria (i.e., MUAC \<110 mm) leads to the selection of more severely malnourished children, who may be at higher risk for relapse (Stobaugh et al., [2017](#mcn12702-bib-0029){ref-type="ref"}). Adhering to the WHO\'s recommended admission and discharge criteria and attempting to reduce default rate may help to lower relapse. Innovative approaches such as teaching mothers to screen children\'s MUAC, the use of community health workers to treat acute malnutrition, and expanded admission criteria which include MAM children in therapeutic treatment, may facilitate lower risk of relapse by improving default rates and early identification of new cases (Ale et al., [2016](#mcn12702-bib-0002){ref-type="ref"}; Maust et al., [2015](#mcn12702-bib-0025){ref-type="ref"}). This review also highlights the importance of early identification of SAM cases such that children receive treatment before experiencing a more severe degree of physiological insult and risk of relapse increases. However, more research is needed to determine the effects of these innovations on relapse rates.

Continuity of care following initial treatment for SAM is crucial for children to reach and maintain lasting recovery. Continued nutritional support, potentially in the form of a supplementary feeding programme, may contribute to lower relapse rates, especially if national protocols call for children to be discharged at MUAC equals 115 mm or WHZ equals −3 (Mengesha, Deyessa, Tegegne, & Dessie, [2016](#mcn12702-bib-0026){ref-type="ref"}). Continued nutritional support may help to progress anthropometric status to the WHO recommended discharge cut‐off of MUAC equals 125 mm or WHZ equals −2. However, it is acknowledged the SFPs vary in design and quality, and although uptake of SFP services reduced odds of relapse in our secondary data analysis, it was not statistically significant. Still, having a higher MUAC and WHZ upon discharge has seen to be protective against relapse in other analyses.

Addressing co‐morbidities by incorporating programmatic linkages to healthcare services and the promotion of appropriate health seeking behaviours may also help to improve the sustainability of recovery following SAM. Post‐discharge mortality is shown to be highest among HIV+ children, demonstrating the need to better integrate antiretroviral treatment and possibly identify therapeutic foods that might cater to the specific nutritional needs of malnourished children with HIV (Kerac et al., [2014](#mcn12702-bib-0021){ref-type="ref"}). In this review, one of the studies with the lowest proportion of relapse, at 0.6%, occurred where study participants lived near a health facility, with 90% of the children visiting the facility at least once, and 53% receiving antibiotics at least once over the course of the 12‐month follow‐up period (Khanum et al., [1998](#mcn12702-bib-0022){ref-type="ref"}). This suggests that routine follow‐up with access to healthcare services among this high‐risk population of post‐SAM children can lead to timely referrals and treatment for illness that may otherwise leave children highly susceptible to morbidity and relapse. Greater availability and quality of follow‐up home visits, integration of primary health care services, and provision of other welfare support post‐discharge, such as cash transfers, may therefore improve relapse rates.

The development of a standard definition of relapse is needed for researchers and programme implementers to better understand the burden of relapse and assess the sustainability of recovery when using current treatment protocols. For research purposes, such standardized reporting of relapse should include the following: a definition of timescale, data collection methods (i.e., systematic tracking vs. passive readmissions), frequency of data collection points within the recommended follow‐up period, clarification for reporting the severity of relapse episodes (i.e., disaggregating between relapse to SAM vs. AM), and disaggregation of those who met the discharge criteria from those who defaulted. Programme reports and studies that do not disaggregate relapses of defaulters from those who reached discharge criteria may need to be interpreted with caution.

Given that this review found the highest risk for relapse occurs during the first 6 months following discharge, and studies measuring relapse following recovery from MAM showed similar timing of relapse post‐discharge (Chang et al., [2013](#mcn12702-bib-0016){ref-type="ref"}; Stobaugh et al., [2017](#mcn12702-bib-0029){ref-type="ref"}), fortnightly follow‐up for the first 3 months is ideal for identifying relapse. Further, monthly follow‐up between 3 and 6 months is also recommended with analysis disaggregated between the first 3 months and the following 3--6 months. Follow‐up of discharged children should be systematically and actively pursued, in addition to referrals from other service providers and readmissions based on self‐referrals at any time during the follow‐up period.

It is also important to distinguish between absolute versus excess relapse (Bahwere, [2016](#mcn12702-bib-0006){ref-type="ref"}). The absolute relapse rate should be compared with the regular incidence of SAM in nonpreviously malnourished children over the same time period in order to estimate the excess burden of relapse. Where possible, longitudinal studies should include a comparison group of nonpreviously wasted children from the same community who are followed alongside post‐SAM children to serve as a control group. This leads to the calculation of expected events for comparison with observed events. In the least, both researchers and programme implementers should present relapse or readmission rates in the context of SAM prevalence in order to better understand the excess acute malnutrition resulted by relapse. The 2015 Ethiopia study\'s follow‐up procedures and use of a nonpreviously wasted control groups serve as a strong example for how to capture excess relapse well (Tsinuel et al., [2015](#mcn12702-bib-0032){ref-type="ref"}).

Such rigorous follow‐up procedures may not be feasible in routine or emergency CMAM programs where resources are limited. In such circumstances, caregivers of discharged children should be requested to return to the CMAM facility at 1, 3, and 6 months post‐discharge to monitor the child\'s progress and reassess for relapse. Although this would likely lead to additional screenings at CMAM facilities, children who relapse will be caught earlier in their regression and thus, in theory, require fewer resources to retreat than otherwise waiting until the child\'s nutritional status deteriorates significantly. If possible, routine CMAM programs should utilize community health workers or volunteers to visit the homes of recovered children at 1, 3, and 6 months post‐discharge if caregivers fail to voluntarily bring the child back to the facility for post‐discharge reassessment. This would allow for more accurate relapse rates than solely relying on voluntary returns. At a minimum, routine programs should emphasize active‐case finding at the community level for both nonpreviously and previously malnourished children, which in turn would not only improve timely identification of new cases but also the capture of relapse, where data records allow.

There is no standard in the literature to assess what rate of relapse is high, low, or acceptable. Evidence is needed to better understand the consequences of relapse in order to determine a target rate of relapse under which treatment programs should aspire to remain. Once there is further data, a maximum acceptable relapse or readmission rate could be added to the Sphere Minimum Standards (*The Sphere Project Handbook*, [2011](#mcn12702-bib-0031){ref-type="ref"}) and included as a regularly collected indicator of programme quality in the treatment of SAM. Also, post‐discharge mortality should be taken into account in order to determine how survivor bias may effect relapse rates, especially in contexts where HIV is prevalent, and the mortality rate is particularly high among post‐discharge SAM children. High mortality may lend to a lower relapse rate and give the false impression that post‐discharge outcomes are not poor. Additional standards for programme monitoring and quality indicators should include minimum community screenings and follow‐up visits of discharged children.

Research, programming, and policy need to shift the focus of acute malnutrition from not only achieving immediate recovery to achieving sustained recovery and improving other long‐term outcomes of children with SAM. Further research is necessary to define relapse and better understand the risk factors and consequences associated with relapse. Studies are warranted regarding the following: identification of children at high risk of relapse, different discharge criteria and its effect on relapse, innovative methods for improving early identification of acute malnutrition, interventions and innovative formulas for therapeutic foods that improve immune function immediately after discharge, and other interventions to reduce relapse in high‐risk children.
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